Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
GSK said on April 15 that it has launched its anti-IL-5 monoclonal antibody Exdensur (depemokimab) in Japan as a long-acting biologic option for the treatment of asthma and chronic rhinosinusitis. The drug — available as a 100 mg subcutaneous pen…
To read the full story
Related Article
BUSINESS
- Vanflyta Wins China Nod for Frontline AML
June 16, 2026
- Otsuka Closes US$700 Million Transcend Buyout
June 16, 2026
- Takeda’s Zasocitinib Beats Sotyktu in PIII Psoriasis Trial
June 15, 2026
- Rakuten Medical CEO-Elect Reaffirms 2028 US Filing Plan for Akalux
June 15, 2026
- Heartseed Starts Japan PI/II of Catheter-Delivered iPSC Cardiomyocyte Therapy
June 15, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…